Triptorelin (trifluoroacetate salt)

Triptorelin (trifluoroacetate salt)

CAT N°: 28613
Price:

From 140.00 119.00

Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) peptide agonist that binds to the GnRH receptor (GnRHR; Ki = 0.3 nM in CHO cells expressing the human receptor).{36464} It inhibits the growth of DU145, LNCaP, and PC3 prostate and OVCAR-3 ovarian cancer cells (IC50s = 62.1, 73.4, 98.1, and 67.7 ?M, respectively).{52097} Triptorelin also inhibits the growth of the triple-negative breast cancer (TNBC) cell lines HCC1806 and MDA-MB-231 (EC50s = 58.29 and 31.59 ?M, respectively).{52096} It stimulates follicle stimulating hormone (FSH) and luteinizing hormone (LH) release from primary rat pituitary cells when used at a concentration of 50 nM.{52097} It also decreases tumor volume of Dunning R3327H prostate tumor flank implants and reduces prostate and testis weight in rats when administered at a dose of 1 mg/kg per day.{39555} Formulations containing triptorelin have been used in the palliative treatment of advanced prostate cancer.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 6-D-tryptophan-luteinizing hormone-releasing factor (swine), trifluoroacetate
  • Correlated keywords
    • LHRH 6D Triptoreline Tryptorelin 6D-LH-RH DU-145 PC-3 OVCAR3 HCC-1806 MDAMB-231 MDAMB231 R-3327-H R3327-H R-3327H AY25650 BIM21003 CL118532 WY42462 WY42422 Trp-6 57773-63-4
  • Product Overview:
    Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) peptide agonist that binds to the GnRH receptor (GnRHR; Ki = 0.3 nM in CHO cells expressing the human receptor).{36464} It inhibits the growth of DU145, LNCaP, and PC3 prostate and OVCAR-3 ovarian cancer cells (IC50s = 62.1, 73.4, 98.1, and 67.7 ?M, respectively).{52097} Triptorelin also inhibits the growth of the triple-negative breast cancer (TNBC) cell lines HCC1806 and MDA-MB-231 (EC50s = 58.29 and 31.59 ?M, respectively).{52096} It stimulates follicle stimulating hormone (FSH) and luteinizing hormone (LH) release from primary rat pituitary cells when used at a concentration of 50 nM.{52097} It also decreases tumor volume of Dunning R3327H prostate tumor flank implants and reduces prostate and testis weight in rats when administered at a dose of 1 mg/kg per day.{39555} Formulations containing triptorelin have been used in the palliative treatment of advanced prostate cancer.

We also advise you